SCHEDULE: BlackRock Discloses 15.6% Stake in NeoGenomics

BlackRock, Inc. has reported a beneficial ownership of 20,358,331 shares, representing 15.6% of the common stock of NeoGenomics Inc., as of June 30, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating a significant beneficial ownership in NeoGenomics Inc.
• The filing reports that BlackRock beneficially owns 20,358,331 shares of NeoGenomics Inc. common stock.
• This ownership stake represents 15.6% of the total outstanding common stock.
• The reporting date for this ownership is June 30, 2026.
• BlackRock, Inc. is identified as a large institutional investor, specifically a holding company.
• The filing clarifies that this report reflects securities owned by certain business units of BlackRock, Inc. and its subsidiaries and affiliates.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard disclosure of institutional ownership and does not contain operational updates or financial performance indicators for NeoGenomics Inc. itself.

Positives

• BlackRock's substantial investment indicates confidence in NeoGenomics Inc.'s long-term prospects.
• A large institutional holder like BlackRock can provide stability and credibility to the company.
• The ownership stake of 15.6% is significant and suggests a strong investor interest.

Risks

• While BlackRock is a passive investor in this filing, any significant shift in their holdings could impact NeoGenomics' stock price.
• The concentration of ownership with a single large entity could potentially limit the free float of shares.

Future Outlook

This filing is a snapshot of ownership as of June 30, 2026, and does not contain forward-looking statements or guidance from NeoGenomics Inc. itself. BlackRock's future actions regarding its stake are not detailed.

Management Comments

• BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant institutional ownership, as reported by BlackRock, is common in the diagnostics and life sciences sector, reflecting investor interest in companies with specialized technologies and market positions. NeoGenomics operates in the cancer genomics testing market, a field experiencing growth driven by advancements in personalized medicine.

Stakeholder Impact

• Shareholders: The significant stake held by BlackRock may influence market perception and trading liquidity. Any changes in BlackRock's holdings could impact share price.
• Management: The presence of a large institutional investor like BlackRock can bring scrutiny and potentially influence strategic decisions, though this filing indicates passive ownership.
• Creditors: Stable institutional ownership can be viewed positively by creditors as it may indicate a more stable corporate environment.

Next Steps

• BlackRock, Inc. will continue to monitor its beneficial ownership and file amendments to Schedule 13G as required by regulatory changes or shifts in its holdings.
• NeoGenomics Inc. will continue its operations in the cancer genomics testing market.

Key Dates

Keywords

NeoGenomics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Healthcare, Diagnostics